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Abstract
Graft-versus-host disease (GvHD) remains the most significant complication after allogeneic stem
cell transplantation (allo-SCT). Previously, acute GvHD had been considered to be mediated
predominantly by Th1 polarized T cells. Recently, investigators have identified a second pro-
inflammatory lineage of T cells termed Th17 that is critically dependent on the transcription factor
RORγt. Here, we have evaluated the role of Th17 cells in murine acute GvHD by infusing donor
T cells lacking RORC and as a consequence the isoform RORγt. Recipients given donor CD4+
and CD8+ T cells lacking RORC had significantly attenuated acute GvHD and markedly
decreased tissue pathology in the colon, liver, and lung. Using a clinically relevant haploidentical
murine transplantation model, we showed that RORC−/− CD4+ T cells alone diminished the
severity and lethality of aGvHD. This was not found when CD4+ T cells from RORC−/− mice
were given to completely mismatched BALB/c mice, and correlated with absolute differences in
the generation of TNF in the colon post transplant. Thus, CD4+ T cell expression of RORC is
important in the pathogenesis of acute GVHD.
Introduction
Allogeneic stem cell transplantation (allo-SCT) is a common treatment for patients with
high-risk leukemia, recurrent low-grade lymphomas, aplastic anemia, and congenital bone
marrow failure syndromes (1-3). The effectiveness of allo-SCT is limited by the
development of acute graft-versus-host disease (aGvHD). aGvHD, a disease characterized
by selective epithelial damage to target organs, is mediated by mature T cells present in the
stem cell or bone marrow inoculums (4-7). Interactions of donor T cells with predominantly
host antigen presenting cells (APC) leads to activation and differentiation of donor T cells
ultimately resulting in inflammation in GvHD target organs, which includes primarily the
skin, liver, and gastrointestinal tract (8).
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Previous GvHD research has focused on cytokine production in T cell subsets. High levels
of interferon γ (IFN-γ) and interleukin-2 (IL-2) found in patients after allo-SCT led
investigators to conclude that GvHD was mediated predominantly by proinflammatory Th1
cells (9, 10). However and conversely, inhibition of Th1 cytokines leads to disease
exacerbation in GvHD (11, 12). As both protective and detrimental effects are seen with Th1
cytokines the exact role of these cytokines in GvHD remains elusive (13). More recent
investigations of T cell subsets in GvHD have been directed towards a new subset of CD4+
T cells, Th17 cells. Th17 cell differentiation and expansion requires TGF-β1, IL-6, IL-23,
TNF, and IL-1β (14-16). The development of Th17 cells is dependent on the transcription
factors retinoid-related orphan receptor (ROR)γt, RORα, IRF-4 and STAT3 (17, 18). Th17
cells produce proinflammatory cytokines such as TNF, IL-21, and IL-22 (19-21) in addition
to IL-17A and IL-17F. IL-21 has been found by our group to be critical for blocking the
generation of inducible Treg cells (19) while IL-22 has been found to be important for the
induction of psoriasis in experimental models (22). IL-17A and IL-17F bind to the IL-17
receptor found on leukocytes, epithelial cells, mesothelial cells, endothelial cells,
keratinocytes, and fibroblasts. Binding of IL-17A and IL-17F to the IL-17 receptor enhances
production of g-CSF, IL-6, and chemokines that recruit neutrophils such as CXCL1 and
CXCL8 (23).
Keppel et al using IL-17A knockout (−/−) CD4+ T cells demonstrated that IL-17 contributes
to aGVHD (24). In contrast, Yi et al has shown that IL-17A−/− T cells exacerbated aGVHD
due to augmented release of IFN-γ (25). Recent studies in our laboratory demonstrated that
in vitro differentiated Th17 cells generated substantial cutaneous and pulmonary pathology
in murine models of aGvHD (26) but multiple pathways may have been involved, with
IL-17A and TNF being dominant. To better understand the effects of Th17 cells that are
differentiated or activated in vivo, we elected not to focus on a particular cytokine effector
pathway such as IL-17A itself, which would limit conclusions that can be drawn regarding
Th17 cells. Instead, we performed studies using RORC−/− donor T cells that are incapable of
producing the array of cytokines generated by Th17 cells including IL-17A, IL-17F, IL-21,
IL-22 and TNF. In the absence of RORC conventional T cells attenuated GvHD in a
haploidentical, minor, and complete mismatched model. The absence of RORC expression
by CD4+ T cells alone was sufficient to attenuate GvHD in the haploidentical model, but
had little impact on GvHD in a complete mismatched model. Interestingly, we found
increased generation of IL-17 from lesional tissue in BALB/c recipient mice even when
transplanted with donor T cells lacking RORC. These data indicate that T cell generation of
RORγt is important to the pathogenesis of acute GvHD.
Methods
Mice
C57BL/6J (H2b) (termed B6), BALB/cJ (H2d), C.B10-H2b/LiMcdJ (termed BALB.b),
B6.129S6-Tbx21tm1Glm/J (termed T-bet−/−), B6 x DBA/2 F1 (B6D2 F1: H2bxd), and
B10.BR-H2k H2-T18a/SjSnJJrep mice were purchased from The Jackson Laboratory (Bar
Harbor, ME). B6 RORC−/− mice were generated as described (27). Donor and recipient
mice were age-matched males between 8 and 16 weeks. All experiments were performed in
accordance with protocols approved by the University of North Carolina Institutional
Animal and Care Use Committee.
Transplantation Models
Total T cells or CD4+ T cells were isolated using Cedarlane T recovery column kit or CD4+
T cell recovery kit (Cedarlane, Burlington, NC) respectively, followed by antibody depletion
using phycoerythrin (PE) conjugated anti-mouse B220 and anti-mouse CD25 antibodies
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(Ebioscience, San Diego, CA) and magnetic bead selection using anti-PE beads (Miltenyi
Biotec, Cambridge, MA). Isolated CD4+ T cell were further purified using anti-mouse CD8
PE antibody. T cell depleted bone marrow bone marrow (TCD BM) and conventional T
cells were prepared using previously described methods (28). Histopathology specimens
were generated as described (29) and analyzed by one of us (APM) blinded to the genotype
of donor used. Scoring of tissues was performed per our previous method (30).
Serum and Organ Cytokine Analysis
Transplant recipient animals were anesthetized and perfused with phosphate-buffered saline.
Whole organs were removed and homogenized. Cytokine levels were measured using
enzyme-linked immunosorbent assay (ELISA) kits against IFN-γ, IL-17A, and TNF
(Biolegend, San Diego CA).
Intracellular Cytokine Staining
Single cells suspensions of livers were digested using collagenase A and DNAse I. Liver
cells were stimulated with phorbol myristate acetate (PMA), ionomycin and brefeldin A for
4 hours. Cells were harvested and stained for anti-mouse TNF (Ebioscience, San Diego,
CA). Flow cytometry analyses were conducted using FlowJo analysis software (Ashland,
OR).
Real Time PCR Analysis
RNA was extracted from organs using TRIzol reagent (Invitrogen, Carlsbad CA) according
to the manufacturer’s recommendations. First strand cDNA synthesis was performed with
1μg RNA as previously described (26). Equal amounts of cDNA were analyzed by real time
quantitative PCR, in triplicate, using TaqMan universal PCR master mix (Applied
Biosystems, Foster City, CA) and the ABI 7300 Real Time PCR System with primer
specific standard curves. The expression level of each gene was normalized to the
housekeeping gene, GusB, using the standard curve method before fold activation was
determined. TaqMan gene expression assay probes for interferon gamma, tumor necrosis
factor, and interleukin 17A/F were purchased from Applied Biosystems.
GvHD Scoring
Mice were observed twice weekly for clinical GvHD signs and symptoms based on a
previously established clinical scoring system (31).
GvL Analysis
Recipient mice were infused with 1 × 104 P815 murine mastocytoma cells (ATCC: TIB-64)
on the transplantation. Weight loss and survival were monitored bi-weekly. Necropsies were
performed on mice to confirm death by tumor infiltration.
Statistical Analysis
Survival differences were evaluated using Mantel-Cox log rank test. Survival curves were
generated using the method of Kaplan and Meier (32). Differences in GvHD clinical and
pathology scores were determined using Mann-Whitney test. P values ≤ 0.05 were
considered statistically significant.
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Attenuated GvHD in the Absence of RORC
Previous work demonstrated that blocking IFN-γ exacerbated aGvHD suggesting that
another T cell lineage may be important in GvHD pathology (12). As our previous work
using in vitro differentiated Th17 cells demonstrated their ability to induce lethal aGvHD,
we used mice in which the RORC locus (RORC−/−) was altered using homologous
recombination to further clarify the contribution of the Th17 subset to GvHD induction
under non-polarizing conditions. These mice lack both RORγ and RORγt isoforms
generated from this locus. CD25-negative (CD25−) naïve whole T cells (comprised of CD4+
T cells and CD8+ T cells; termed Tconv) from WT C57BL/6 (WT) or RORC−/− donors were
transferred into lethally irradiated B6D2 F1 recipients. In addition to T cells, mice were
injected with T cell depleted bone marrow (TCD BM) cells from WT donors. Recipient
mice given RORC−/− Tconv had a substantial improvement in survival with all B6D2 F1
recipient mice surviving until day 60 post transplantation (Fig 1a). Using a semi-quantitative
scoring system we evaluated the clinical manifestations of aGvHD (33) in B6D2 F1
recipient mice. A significant difference in the aGvHD score starting on day 10 and
continuing through the completion of the experiment was found in irradiated B6D2 F1
recipient mice transplanted with RORC−/− Tconv compared to WT Tconv (Fig 1b).
To determine whether the reduced aGVHD lethality observed with the infusion of RORC−/−
Tconv vs WT Tconv was model dependent, we evaluated two additional transplantation
models. Lethally irradiated BALB/c mice given CD25-depleted donor Tconv from either
WT or RORC−/− donors with WT TCD BM had improved median survival (Fig 1c) with a
diminished GvHD score (Fig 1d) when receiving RORC−/− compared to WT Tconv.
Similarly, the median survival was improved when BALB.B mice were administered
RORC−/− Tconv compared to WT Tconv (Supp Fig 1). However, in BALB.B recipients,
there was only a transient improvement in GvHD score from days 10-17 post transplant.
Thus, in three different GvHD models using CD25-depleted Tconv, the absence of RORC in
donor T cells improved survival.
Decrease Tissue Pathology in GvHD Target Organs using RORC−/− Donor T Cells
Clinically, multiple organs can be affected in aGvHD including the skin, liver, GI tract and
the lung. To determine if RORC−/− Tconv affected aGvHD at a specific site we evaluated
the tissue pathophysiology in the liver, GI tract, lung and spleen of RORC−/− Tconv
recipients compared to WT Tconv recipients. Fifteen days post transplantation the organs of
recipient animals were harvested and pathology analyses conducted. Recipients of RORC−/−
Tconv displayed significantly less pathology in the liver, colon, lung, and spleen compared
to WT Tconv recipients (p< 0.05, Fig 2). Decreased pathology in recipient mice transplanted
with RORC−/− donor Tconv was specific to GvHD target organs as minimal GvHD
pathology was detected in the kidney of WT and RORC−/− Tconv recipients. The aggressive
nature of GI tract GvHD precluded the development of significant cutaneous GvHD in this
model, and therefore cutaneous tissue was not evaluated. These data demonstrate that the
function of RORC in the pathophysiology of aGvHD is not limited to a specific organ site.
In Vivo Cytokine Production Using RORC−/− Tconv Cells
Th17 cells generate a number of cytokines that may be important to the pathogenesis of
aGvHD such as TNF, IL-17F, IL-21, and/or IL-22. Cytokine analyses were performed on
serum and organ samples from RORC−/− Tconv vs WT Tconv in B6D2 F1 recipients on day
14 post transplantation. Interestingly, the administration of donor T cells unable to express
RORC was associated with a modest increase in the production of IFN-γ in the serum of
recipient mice compared to those receiving WT Tconv (Fig 3a). A substantial decrease in
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IL-17 and TNF were seen in the serum of recipients RORC−/− Tconv compared to WT
Tconv recipients (Fig 3a). The decrease in TNF production in the serum was associated with
statistically significant decreased production of TNF in the colon however no differences
were seen in cytokine production in other organs (Fig 3b).
To determine if the lack of differences in pro-inflammatory cytokines outside of the
difference in the generation of TNF in the colon was due to the time point we evaluated, we
analyzed mRNA expression of IFN-γ, and IL-17A from lesional tissue on days 10 and 18
post transplantation. No difference was found in the expression of these cytokines in the
colon, liver or spleen of recipients of WT compared to RORC−/− T cells plus TCD B6 bone
marrow. Thus, the absence of RORC in donor T cells led to a marked decrease in the
generation systemically of the pro-inflammatory cytokines TNF and IL-17A, and of TNF
specifically in the colon.
RORC−/− CD4+ T Cells Mediate GvHD in a Haploidentical Transplantation
Previous investigators have found that the infusion of donor T cells lacking RORC did not
affect the incidence or severity of aGvHD when administered to lethally irradiated BALB/c
recipients (34). However, the T cell inoculum for these experiments was comprised
exclusively of CD4+ T cells. The difference found by our group in the outcome of BALB/c
recipients receiving RORC−/− T cells occurred when infusing CD4+ and CD8+ T cells. To
determine if the different T cell inoculums mediate the changes in outcome initially, we
confirmed the data from Icozlan et al. BALB/c mice receiving RORC−/− CD4+ T cells did
not have improved survival or GvHD scores compared to recipients given WT CD4+ T cells
(Fig 4a). Next, we determined if the absence of RORC by donor CD4+ T cells would impact
the outcome in the haploidentical B6 into B6D2 model. All B6D2 recipients of RORC−/−
CD4+ T cells survived until completion of the experiment with minimal evidence of clinical
GvHD, while recipients of WT CD4+ T cells succumbed to disease by day 35 post
transplantation (Fig 4b). This indicated that the difference in the outcome of recipient mice
given donor RORC−/− CD4+ T cells was model dependent. These data demonstrate a
requirement for RORC CD4+ T cell expression for GvHD pathogenesis in the haploidentical
transplant setting.
Cytokine Production in RORC−/− CD4+ T Cell Recipients
Differences in outcome using RORC−/− CD4+ T cells in the haploidentical versus the
complete mismatch model are likely due to increased genetic disparity and potentially
increased GvHD due to the ability of a smaller number of donor T cells to mediate GvHD,
or GvHD mediated through different pro-inflammatory pathways. To elucidate the
differences in outcome using RORC−/− CD4+ T cells in the B6 into BALB/c transplant
model compared to the B6 into B6D2 transplant model, we evaluated cytokine production in
the serum and organs from recipient animals. Lethally irradiated B6D2 recipients were
transplanted with 3 × 106 RORC−/− or WT CD4+ T cells with 3 × 106 WT TCD BM cells
while lethally irradiated BALB/c recipients were infused with 5 × 105 RORC−/− or WT
CD4+ T cells supplemented with 5 × 106 WT TCD BM cells. Serum and tissue homogenates
from the liver, GI tract, lung and spleen were collected from recipients 14 days post
transplantation. We found that B6D2 recipients of RORC−/− CD4+ T cells had increased
TNF production in the serum with decreased IFN-γ production compared to B6D2
recipients of WT CD4+ T cell (Fig 4c), however neither of these values reached statistical
significance. B6D2 recipients of RORC−/− CD4+ T cells had a significant decrease in the
production of TNF and IFN-γ in the colon compared to B6D2 recipients of WT CD4+ T
cells (Fig 4d). This was not found in BALB/c recipients given either RORC−/− or WT donor
CD4+ T cells. Interestingly, IL-17 production in the liver of BALB/c recipients was 8 times
higher than IL-17 production in B6D2 recipients (Fig 4d) and not altered by the infusion of
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donor T cells lacking RORC. To determine if differences in the production of IL-17A was
specific to BALB/c recipients, we analyzed a second MHC mismatched model. Lethally
irradiated B10.BR mice were injected with 3 × 106 WT or RORC−/− CD4+ T cells with 3 ×
106 TCD BM. TNF and IFN generation in the liver and colon of B10.BR recipients did not
differ in the absence of RORC−/−. Interestingly, similar to BALB/c recipients, increased
expression of IL-17 was seen in recipient B10.BR mice given either RORC−/− or WT CD4+
T cells (Fig 4d). These data suggest that the generation of IL-17A in the completely
mismatched MHC transplant models is more dependent on production by cells other than
donor T cells. Moreover, we found that the absence of RORC in donor T cells mediated
protection against GvHD only in models in which there was a decrease in the production of
TNF systemically and in the colon after the infusion of RORC−/− T cells.
RORC and TNF Production
Our data indicate a role for RORC in the function of CD4+ T cells in the haploidentical
transplant model. To determine if there was a function for RORC in donor CD8+ T cells, we
transplanted mice with either RORC or WT CD4+ or CD8+ T cells. Three cohorts of lethally
irradiated B6D2 F1 recipients were used for these experiments. One group received 2 × 106
RORC−/− CD4+ T cells with 2 × 106 WT CD8+ T cells supplemented with 3 × 106 TCD BM
cells. A second group received 2 × 106 WT CD4+ T cells with RORC−/− CD8+ T cells
supplemented with 3 × 106 WT TCD BM cells. A final group received only 3 × 106 TCD
BM cells. Interestingly, more than 80 percent of mice that received RORC−/− CD4+ T cells
with WT CD8+ T cells survived until day 50 post transplantation while those receiving WT
CD4+ T cells with RORC−/− CD8+ T cells died from GvHD by day 30 post transplantation
(Fig 5a). Intracellular cytokine analyses of TNF and IFN-γ production were conducted on T
cells isolated from liver of WT CD4+ T, RORC−/− CD8+ T cell and RORC−/− CD4+, WT
CD8+ T cell recipients 10 days post transplantation. Overall production of both TNF and
IFN-γ were equivalent between the two groups. However in both cohorts independent of
whether RORC−/− CD4+ T cells or RORC−/− CD8+ T cells were injected, WT T cells were
the primary producers of TNF (Fig 5b). These data suggest that the production of TNF by
CD4+ and not CD8+ T cells is critical to the pathogenesis of GvHD in this model.
Tissue Specific Role for T-bet in aGvHD
To determine if the inability to produce proinflammatory cytokines was sufficient to
attenuate aGvHD we investigated the transcription factor that controls the expression of the
Th1 cytokine IFN-γ, Tbx21(T-bet). Donor CD25− Tconv from T-bet−/− or WT mice
supplemented with WT TCD BM were transplanted into lethally irradiated B6D2 F1
recipients. Interestingly, in this model, no difference was found in survival or GvHD score
in mice receiving WT compared to T-bet−/− Tconv (Fig 6a). However, analysis fifteen days
post transplantation revealed statistically significant decreased pathology in the ileum of
recipients of T-bet−/− compared to wild type Tconv cells (p< 0.05, Fig 6b). A trend for
decreased pathology was also seen in the colon (p = 0.08, Fig 6b). However, we did not find
a difference in tissue pathology in other GvHD target organs given WT compared to T-
bet−/− T cells (data not shown). These data support the established function for Th1 cells in
the pathophysiology of GvHD in the GI tract, but indicate that in this haploidentical
transplant model, T cell generation of T-bet was not critical for GvHD lethality (35).
GvL Response in the Absence of RORC
Next, we addressed whether the loss of RORC would impact the anti-tumor activity of SCT.
Anti-tumor activity after transplantation was evaluated by adding 1 × 104 P815 cells to the
donor bone marrow inoculum on day 0. One group of B6D2 F1 mice received RORC−/−
Tconv cells in addition to WT TCD BM cells infused with P815 tumor cells. Since
recipients of WT Tconv often succumb to GvHD before anti-tumor properties can be
Fulton et al. Page 6













analyzed syngeneic T cells were used as a control. Syngeneic controls were given B6D2
Tconv supplemented with WT TCD BM infused with P815 tumor cells. Control mice
received only WT TCD BM infused with P815 tumor cells. All mice receiving only WT
TCD BM with P815 tumor cells died by day 20 due to tumor growth. Recipient mice
receiving B6D2 Tconv died by day 20 due to tumor infiltration (Fig 7). Interestingly,
survival was extended to day 40 in recipient mice given RORC−/− Tconvs and P815 cells
indicating that the GvL response remained somewhat intact in mice given T cells lacking
RORC. To demonstrate that this difference was not mediated by donor bone marrow cells,
we administered RORC−/− TCD BM or WT TCD BM cells plus P815 cells to lethally
irradiated B6D2 F1 recipient mice. As expected all recipient mice succumbed to tumor
infiltration by day 30 (data not shown).
Discussion
Acute GvHD is mediated by donor T cells that recognize minor or major MHC disparities
presented predominantly by host APCs. This process leads to activation, differentiation and
T cell effector responses that are critical for the pathophysiology of acute GvHD. Over the
past decade multiple investigators have identified new T cell subsets characterized by the
activity of canonical transcription factors and the generation of specific cytokines. The T
cell subset(s) critical for the pathophysiology of acute GvHD is currently unclear and the
focus of this manuscript. Here, we find unexpectedly that the loss of the Th17 transcription
factor, RORC, in donor CD25-depleted T cells led to markedly diminished acute GvHD. In
three different models, recipient mice given RORC−/− Tconv cells had significantly less
GvHD and increased survival compared to recipients given WT Tconv cells. The absence of
RORC was associated with diminished GvHD in all target organs evaluated and correlated
with diminished systemic generation of pro-inflammatory cytokines. The difference in
pathology of GvHD target organs was not associated with a difference in frequency of
regulatory T cells in these organs post transplant (Fulton and Serody unpublished). As was
previously found, the absence of RORC on CD4+ T cells had no effect on GvHD outcome in
a completely mismatched B6 into BALB/c model. Interestingly, in the B6 into B6D2 model,
the absence of T-bet in donor T cells led to diminished pathology in the GI tract but no
overall survival benefit. When challenged with P815 tumor cells, recipient mice receiving
donor T cells lacking RORC survived longer than mice receiving bone marrow alone,
indicating the presence of an anti-tumor GvL response. However, in both instances recipient
mice succumbed eventually to tumor growth indicating that the GvL response is modestly
compromised using T cells unable to generate RORC perhaps due to the diminished
generation of TNF.
Previous work has clearly indicated a critical role for Th1/Tc1 T cells in the
pathophysiology of acute GvHD particularly involving the GI tract. Thus, it was somewhat
unexpected that the absence of T-bet alone, while diminishing GvHD in the small bowel and
to a lesser extent the colon, was not associated with an improved overall survival. T-bet has
been found to be critical for the generation of IFN-γ by CD4+ T cells and NK cells.
However, the generation of IFN-γ by CD8+ T cells is not impaired in the absence of T-bet,
which may be responsible for the similar survival (36). As we have found that RORC is
required in the CD4+ T cell compartment, our data would be consistent with a role for IFN-
γ generation by CD8+ T cells and TNF production by CD4+ T cells in the pathogenesis of
acute GvHD.
Quite recently, Yu et al evaluated the ability of T cells from mice deficient in RORC or
Tbx21 to induce GvHD (37). They found diminished GvHD using T cells from B6 Tbx21−/−
donors but no difference in GvHD using CD4+ T cells from RORC−/− donors when given to
lethally irradiated BALB/c recipients. Interestingly, they did find a modest survival benefit
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when infusing CD25-depleted T cells lacking RORC suggesting that the Treg compartment
may not function in RORC mice as it does in WT mice. They found that BALB/c recipient
mice given T cells from mice deficient in both RORC and Tbx21 had markedly diminished
GvHD. This was associated with diminished generation of Th1 and Th17 cells and impaired
expression of chemokine receptors important for the trafficking of donor T cells to GvHD
target organs. Our data confirm and extend these findings as they relate to the function of
RORC by evaluating the mechanism for the decreased GvHD when CD25-depleted donor T
cells lacking RORC are given to lethally irradiated recipients. Additionally, we confirmed
their previous data regarding the absence of an effect by infusing CD4+ T cells lacking
RORC in the B6 into BALB/c model. We found substantially increased IL-17 in the colon
and liver of BALB/c compared to B6D2 recipient mice after transfer of B6 T cells and TCD
BM. Interestingly, the production of IL-17 was not impacted by the infusion of T cells
lacking RORC suggesting that other donor or perhaps host cells generate substantial
quantities of IL-17 in BALB/c recipients. Currently, we are evaluating which recipient cells
generate IL-17 in BALB/c mice. Nonetheless, these data indicate that the model used may
be critically important in interpreting the function of IL-17 after bone marrow
transplantation.
We found a substantial difference in the generation of TNF and IL-17A in the serum and
TNF in the colon of recipient mice given RORC−/− compared to WT T cells. Our previous
data has indicated that TNF is critical for the systemic manifestations of GvHD mediated by
Th17 cells. Interestingly, here we found that TNF production by CD4+ and/or CD8+ T cells
was markedly reduced when that subset did not express RORC. However, this was
compensated for by production of TNF from the WT T cells when both were given.
However, GvHD was decreased only when TNF production was diminished by CD4+ T
cells and not from CD8+ T cells indicating cell intrinsic differences in the function of TNF
post SCT. We found an increase in the generation of dual positive IL-17A/IFN-γ T cells
when WT Tconv cells were infused compared to RORC−/− Tconv cells 12 days post
transplantation (Supp Fig 2). The generation of these cells, which may eventually become
Th1 cells (Carlson and Serody unpublished), may be one mechanism for the decreased
incidence and severity of aGvHD after the infusion of T cells unable to generate RORC.
For allogeneic transplantation to be successful requires the elimination of GvHD without
compromising the anti-tumor, GvL activity of donor T cells. Here we found that donor T
cells lacking RORC still mediated an anti-tumor response against the mastocytoma cell line,
P815. Killing of P815 cells is dependent on the generation of IFN-γ and TNF (38). This
suggests that the decreased generation of TNF in the absence of RORC is not sufficient to
completely lose the anti-tumor activity of donor T cells.
In summary, we have shown that donor T cells lacking RORC do not mediate substantial
acute GvHD in three different transplant models. This finding is dependent on the absence
of RORC in CD4+ T cells, correlated with reduced generation of TNF and IL-17A
systemically and TNF in the colon, and was important for the diminished GvHD that
occurred in clinically relevant transplant models.
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Figure 1. Survival and GvHD scores of B6D2 recipients
(A-B) B6D2 recipients were lethally irradiated (950 cGy) on day -1. One day following
irradiation, 4 × 106 WT or RORC−/− CD25-Tconv cells supplemented with 3 × 106 TCD
BM were injected intravenously into recipient mice. Recipient mice were monitored and
scored weekly. Control mice received TCD bone marrow cells alone (C-D) BALB/c
recipients were lethally irradiated (800 cGy) on day -1. One day after irradiation, 5 × 105
WT or RORC−/− CD25-T cells supplemented with 5 × 106 WT TCD BM cells were injected
intravenously into irradiated recipients. Survival was determined using the method of
Kaplan-Meier. Statistics determined using log-rank test for survival and Mann-Whitney for
scores. *p<0.05, **p<0.001. A-B n = 13 B6D2 F1 recipients transplanted with RORC−/− or
WT Tconvs; n = 4 bone marrow controls; C-D n = 11 Balb/c recipients given RORC−/−
Tconvs and 8 Balb/c recipients given WT Tconvs; n = 3 BM controls. Data are combined
from 2 individual experiments.
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Figure 2. Decreased tissue pathology in recipient mice given RORC−/− donor T cells
4 × 106 (CD25−) Tconv cells from RORC−/− or WT mice with WT TCD BM were
transplanted into lethally irradiated (950 cGy) B6D2 F1 recipients. Organs were harvested
on day 15 post-transplantation and processed as described. Tissues were evaluated by one of
us (APM) blinded to the treatment group and scored using a semi-quantitative GvHD
scoring system. Shown are the mean scores with error bars indicating SEM. Statistical
significance was determined using Mann-Whitney test, *p<0.05. n = 5 mice analyzed given
WT or RORC−/− T cells. n=4 for bone marrow controls. Data pooled from an individual
transplant using RORC−/− or WT Tconv.
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Figure 3. Increased serum IFN-γ and decreased TNF expression RORC−/− recipients
WT TCD BM and RORC−/− or WT Tconv were transplanted into lethally irradiated B6D2
mice. 14 days post transplantation (A) serum and (B) organs were collected from B6D2 F1
recipients and analyzed by ELISA for the expression of IL-17, TNF and IFN-γ. Shown are
the mean values with error bars representing SEM. Data are pooled from 5 individual B6D2
receiving mice RORC−/− or WT Tconv. Statistical analyses were conducted using Mann-
Whitney test. Data are combined from 2 individual experiments *p<0.05, **p<0.01
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Figure 4. Function of RORC in Donor CD4+ T cells is Model Dependent
(A) Lethally irradiated BALB/c recipients were injected with 5 × 105 RORC−/− CD4+ or
WT CD4+ T cells supplemented with 5 × 106 WT TCD BM. Survival and GvHD scores are
shown. n= 9 for RORC−/− recipients. n=9 for WT recipients, n=4 for bone marrow only
recipients. (B) Lethally irradiated B6D2 F1 recipients were injected with 2 × 106 RORC−/−
CD4+ T cells or WT CD4+ T cells supplemented with 3 × 106 WT TCD BM. n= 7 for
RORC−/− CD4+ T cells, n=7 for WT CD4+ T cells, n=3 bone marrow only. p<0.05 for
survival. p < 0.05 from day 17 until the completion of the experiment for the difference in
GvHD score. Data are combined from 2 individual experiments. (C) Serum and (D) organs
were harvested from lethally irradiated BALB/c, B6D2 F1, or B10.BR recipients
transplanted with RORC−/− or WT CD4+ T cells 14 days post transplantation. WT B10.BR
recipients were harvested 10 days post transplantation. TNF, IFN-γ, and IL-17 production
were determined by ELISA. Data pooled from 5 RORC−/− CD4+ T cell BALB/c recipients
and 4 WT CD4+ T cell BALB/c recipients, 6 RORC−/− CD4+ T cell B6D2 recipients and 4
WT CD4+ T cell B6D2 recipients, 4 RORC−/− CD4+ T cell B10.BR and 3 WT CD4+ T cell
B10.BR recipients. Statistical analysis determined by Mann-Whitney test. * p<0.05.
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Figure 5. Attenuated GvHD using RORC−/− Tconv cells is mediated by CD4+ T cells
(A) Lethally irradiated B6D2 F1 mice were injected with 3 × 106 TCD BM. In addition to
BM one group received 2 × 106 RORC−/− CD4+ T cells and 2 × 106 WT CD8+ T cells, one
group received 2 × 106 WT CD4+ T cells and 2 × 106 RORC−/− CD8+ T cells, and a final
group received only BM cells. Recipients of RORC−/− CD4+ T cells with WT CD8+ Tcells
showed less GvHD reaching statistical significance by day 15 post transplantation. n= 11
recipient mice receiving RORC−/− CD4+ T cells and WT CD8+ T cells, n=5 for recipient
mice receiving WT CD4+ T cells and RORC−/− CD8+ T cells, n=4 for bone marrow only.
Data are combined from 2 individual experiments *p<0.05. (B) 10 days post transplantation
the livers of RORC−/− CD4+, WT CD8+ T cell or WT CD4+, RORC−/− CD8+ T cell
recipient mice were harvested and T cells isolated. Data are representative from 3 WT CD4,
RORC−/− CD8+ recipients and 4 RORC−/− CD4+, WT CD8+ recipients.
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Figure 6. T-bet−/− Tconv cells decrease pathology in the GI tract but do not attenuate GvHD
(A) B6D2 F1 recipient mice were lethally irradiated (950 cGy) on day -1. Following
irradiation on day 0 mice were injected intravenously with 4 × 106 WT or T-bet−/− Tconv
cells supplemented with 3 × 106 WT TCD BM. Mice were monitored for survival and
scored twice weekly for clinical GvHD. n=14 for T-bet−/− recipients, n=11 for WT
recipients, n=4 bone marrow only. All recipient mice receiving BM only cells survived until
the completion of the experiment. (B) On day 15 post transplantation organs were harvested
from WT and T-bet−/− recipients and evaluated for pathology as described above. Error bars
indicate SEM. Statistical significance was determined using Mann-Whitney test. *p<0.05, #
p=0.09. Data are combined from 2 individual experiments.
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Figure 7. Improved anti-tumor responses in the absence of RORC
Lethally irradiated B6D2 F1 mice were injected with 3 × 106 TCD BM with or without 4 ×
106 WT B6D2 or RORC−/− Tconv cells. Additionally all recipient mice received 1 × 104
P815 cells with the BM inoculum. Survival was determined by Kaplan and Meier method.
An improvement in overall survival was found in B6D2 F1 mice given RORC−/− Tconv
cells compared to B6D2 T cells or BM + P815 cells (p < 0.05). n=7 recipients receiving
RORC null T cells, n=5 recipients receiving B6D2 T cells, n=4 recipients receiving BM.
Data combined from 2 individual experiments.
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